Aortic dissection
Conditions
Interventions
Double in situ fenestration technique group:None
Sponsors
Mingli Levin Li
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1.patients aged over 18 2.diagnosed with Stanford Type A aortic dissection, including cases of intramural hematoma 3. Clinical diagnosis: The patient must have a definitive clinical diagnosis of acute type A aortic dissection. This diagnosis is usually based on clinical signs and symptoms, imaging (CT), and laboratory tests as necessary to ensure a firm diagnosis. 4. Severity of disease: conditions ranging from relatively mild to extremely severe will be included. This helps to evaluate the effectiveness of the new treatment in patients of varying severity. 5. Applicability: Patients must meet the criteria for the new treatment, such as appropriate aortic anatomy. 6. Comorbid Medical History: Each patient's co-morbid medical history will be included and analyzed to assess the impact of these potential factors on the treatment. These include hypertension, diabetes, cardiovascular disease, and smoking. 7. Gender and Race: The study should avoid any discrimination on the basis of gender or race and ensure that all patients are treated fairly, therefore this study will not be restricted by gender or race.
Exclusion criteria
Exclusion criteria: 1. non-type A aortic dissection: patients who are not recognized as having acute type A aortic dissection are specifically excluded to ensure that the study population meets the study objectives. 2. no definitive diagnosis: patients without a definitive clinical diagnosis are excluded to ensure that the study cases are confirmed cases of acute type A aortic dissection. 2. No definitive diagnosis: Patients without a definitive clinical diagnosis are excluded to ensure that the study population is comprised of confirmed cases of acute type A aortic dissection. 3.without having dissection induced by trauma or exhibiting risk factors such as pregnancy or a history of cardiac surgery. 4. preoperative death or inoperable patients: exclude patients who die after diagnosis but before surgery, and patients who are unsuitable for surgical intervention because it is not possible. 5. objections to participation: explicitly exclude patients who do not wish to undergo surgery or forgo resuscitation, even if they meet other inclusion criteria. 6. other therapeutic interventions: exclude patients who have already received other therapeutic interventions or surgical interventions to ensure that the study is conducted in patients who have not received other relevant treatments prior to the new treatment. 7. insufficient clinical data: exclude patients for whom clinical data are incomplete or unavailable to ensure that the data set analyzed is of high quality and comparable. 8. unsuitable for the new treatment: patients who do not meet the suitability criteria for the new treatment are explicitly excluded to ensure that the study population can benefit from the new treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| red blood transfusion within the first 24 hours after surgery;average cardiopulmonary bypass duration;average aortic clamp time;average circulatory arrest time;mean extubation time;length of stay in the ICU;duration of hospitalization;Early mortality rate;Late mortality rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Endoleaks;false lumen thrombosis rate;Freedom rates from further intervention rates;Early complication rates;Late complication rates; | — |
Countries
China
Contacts
Public ContactMingli Levin Li
China Medical University Hospital, Taichung City, Taiwan (R.O.C.)
Outcome results
None listed